Efficacy, Safety, and Medication Cost Implications of Adalimumab 40 mg Weekly Dosing in Psoriasis Patients with Sub-Optimal Response to 40 mg Every Other Week Dosing: Results from an Open-Label Study

British Journal of Dermatology, 05/11/2012

Most patients did not require dose escalation. By 12 weeks after dose escalation, one–quarter achieved substantial clinical improvement. Safety results were similar between patients who dosage–escalated and those who did not.

Print Article Summary Cat 2 CME Report